PITCH SPEAKERS

Taku Nakahara

Metagen Therapeutics, Inc.

Founder and CEO

Taku started his carrier as a scientist in the field of bioinformatics. Then he moved to New Jersey to start a biotech in analytics/diagnostics field. After that entrepreneurial experience, he worked for Japanese large enterprise and venture capitals to learn startup investment. In 2020, he and three top-tier researchers in the microbiome fields founded Metagen Therapeutics, Inc. In this company, he successfully raised approx. 2 billion JPY and obtained 10 billion Japanese government grant. He received Ph.D. in Bioinformatics from Hokkaido University (Japan) and MBA from Rutgers Business School (NJ, USA).

Metagen Therapeutics is a biotech startup developing Fecal Microbiota Transplantation for treating patients with gut dysbiosis. For treating ulcerative colitis, our medical service platform is approved as an advanced medical care B program by the Ministry of Health, and our drug development program awarded 10B JPY Japanese government grant. Besides those programs, we also launched programs for immuno-oncology and Parkison's disease. Because the raw material of the treatment is human feces. we are developing "Red Cross for poops". We believe Japanese poops save the patients all over the world.